These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 17380152)

  • 1. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.
    Trusheim MR; Berndt ER; Douglas FL
    Nat Rev Drug Discov; 2007 Apr; 6(4):287-93. PubMed ID: 17380152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety.
    Beitelshees AL; McLeod HL
    Trends Pharmacol Sci; 2006 Sep; 27(9):498-502. PubMed ID: 16876261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redesigner drugs.
    Dove A
    Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice.
    Ross JS; Ginsburg GS
    Am J Clin Pathol; 2003 Jan; 119(1):26-36. PubMed ID: 12520694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A change in the market--investing in diagnostics.
    Batchelder K; Miller P
    Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges of drug discovery for personalized medicine.
    Jain KK
    Curr Opin Mol Ther; 2006 Dec; 8(6):487-92. PubMed ID: 17243483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial biomarkers: From early toxicology assays to patient population profiling.
    Koop R
    Drug Discov Today; 2005 Jun; 10(11):781-8. PubMed ID: 15922936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using controlled clinical trials to learn more about acute drug-induced liver injury.
    Watkins PB; Seligman PJ; Pears JS; Avigan MI; Senior JR
    Hepatology; 2008 Nov; 48(5):1680-9. PubMed ID: 18853438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In biomarkers we trust?
    Baker M
    Nat Biotechnol; 2005 Mar; 23(3):297-304. PubMed ID: 15765081
    [No Abstract]   [Full Text] [Related]  

  • 13. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.
    Eichler HG; Pignatti F; Flamion B; Leufkens H; Breckenridge A
    Nat Rev Drug Discov; 2008 Oct; 7(10):818-26. PubMed ID: 18787530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 15. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are predictive biomarkers of toxicity worth having? An economic model.
    Jones B; Smith DA; Schmid EF
    Xenobiotica; 2012 Jan; 42(1):4-10. PubMed ID: 21970747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of best investing in vaccines: the Health Technology Assessment approach.
    La Torre G; de Waure C; Chiaradia G; Mannocci A; Specchia ML; Nicolotti N; Ricciardi W
    Vaccine; 2008 Mar; 26(13):1609-10. PubMed ID: 18289744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The year's new drugs and biologics--2007.
    Graul AI; Prous JR; Barrionuevo M; Bozzo J; Castaner R; Cruces E; Revel L; Rosa E; Serradell N; Sorbera LA
    Drug News Perspect; 2008; 21(1):7-35. PubMed ID: 18301807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic aspects of pharmacovigilance in the pharmaceutical industry].
    Abadie E; Souetre E
    Therapie; 1993; 48(2):125-7. PubMed ID: 8351680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
    Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT
    Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.